Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota.
HIV
metformin
microbiota
nondiabetic
weight
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
17
07
2020
accepted:
03
08
2020
entrez:
23
9
2020
pubmed:
24
9
2020
medline:
24
9
2020
Statut:
epublish
Résumé
People with HIV (PWH) taking antiretroviral therapy (ART) may experience weight gain, dyslipidemia, increased risk of non-AIDS comorbidities, and long-term alteration of the gut microbiota. Both low CD4/CD8 ratio and chronic inflammation have been associated with changes in the gut microbiota of PWH. The antidiabetic drug metformin has been shown to improve gut microbiota composition while decreasing weight and inflammation in diabetes and polycystic ovary syndrome. Nevertheless, it remains unknown whether metformin may benefit PWH receiving ART, especially those with a low CD4/CD8 ratio. In the Lilac pilot trial, we recruited 23 nondiabetic PWH receiving ART for more than 2 years with a low CD4/CD8 ratio (<0.7). Blood and stool samples were collected during study visits at baseline, after a 12-week metformin treatment, and 12 weeks after discontinuation. Microbiota composition was analyzed by 16S rDNA gene sequencing, and markers of inflammation were assessed in plasma. Metformin decreased weight in PWH, and weight loss was inversely correlated with plasma levels of the satiety factor GDF-15. Furthermore, metformin changed the gut microbiota composition by increasing the abundance of anti-inflammatory bacteria such as butyrate-producing species and the protective Our study provides the first evidence that a 12-week metformin treatment decreased weight and favored anti-inflammatory bacteria abundance in the microbiota of nondiabetic ART-treated PWH. Larger randomized placebo-controlled clinical trials with longer metformin treatment will be needed to further investigate the role of metformin in reducing inflammation and the risk of non-AIDS comorbidities in ART-treated PWH.
Sections du résumé
BACKGROUND
BACKGROUND
People with HIV (PWH) taking antiretroviral therapy (ART) may experience weight gain, dyslipidemia, increased risk of non-AIDS comorbidities, and long-term alteration of the gut microbiota. Both low CD4/CD8 ratio and chronic inflammation have been associated with changes in the gut microbiota of PWH. The antidiabetic drug metformin has been shown to improve gut microbiota composition while decreasing weight and inflammation in diabetes and polycystic ovary syndrome. Nevertheless, it remains unknown whether metformin may benefit PWH receiving ART, especially those with a low CD4/CD8 ratio.
METHODS
METHODS
In the Lilac pilot trial, we recruited 23 nondiabetic PWH receiving ART for more than 2 years with a low CD4/CD8 ratio (<0.7). Blood and stool samples were collected during study visits at baseline, after a 12-week metformin treatment, and 12 weeks after discontinuation. Microbiota composition was analyzed by 16S rDNA gene sequencing, and markers of inflammation were assessed in plasma.
RESULTS
RESULTS
Metformin decreased weight in PWH, and weight loss was inversely correlated with plasma levels of the satiety factor GDF-15. Furthermore, metformin changed the gut microbiota composition by increasing the abundance of anti-inflammatory bacteria such as butyrate-producing species and the protective
CONCLUSIONS
CONCLUSIONS
Our study provides the first evidence that a 12-week metformin treatment decreased weight and favored anti-inflammatory bacteria abundance in the microbiota of nondiabetic ART-treated PWH. Larger randomized placebo-controlled clinical trials with longer metformin treatment will be needed to further investigate the role of metformin in reducing inflammation and the risk of non-AIDS comorbidities in ART-treated PWH.
Identifiants
pubmed: 32964062
doi: 10.1093/ofid/ofaa338
pii: ofaa338
pmc: PMC7489545
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa338Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
Biotechnol Lett. 2005 Sep;27(18):1337-47
pubmed: 16215847
HIV Med. 2016 Apr;17(4):255-68
pubmed: 26216031
Sci Transl Med. 2013 Jul 10;5(193):193ra91
pubmed: 23843452
J Comput Biol. 2017 Nov;24(11):1138-1143
pubmed: 28715235
BMJ Open. 2019 Apr 20;9(4):e028444
pubmed: 31005944
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19584
pubmed: 25394090
J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):527-531
pubmed: 28825943
J Biol Chem. 2004 May 14;279(20):20767-74
pubmed: 14985344
Mediators Inflamm. 2017;2017:8392523
pubmed: 28246439
PLoS One. 2015 Dec 23;10(12):e0143740
pubmed: 26699870
JAMA. 2006 Aug 16;296(7):844-54
pubmed: 16905789
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2247-52
pubmed: 24390544
Microbiome. 2019 May 11;7(1):73
pubmed: 31078141
Diabetes. 2008 Jun;57(6):1470-81
pubmed: 18305141
Nat Med. 2019 Jul;25(7):1096-1103
pubmed: 31263284
Science. 2018 Nov 16;362(6416):770-775
pubmed: 30442801
JAMA Oncol. 2019 Sep 5;:e192553
pubmed: 31486833
Adv Nutr. 2018 Jan 1;9(1):21-29
pubmed: 29438462
Nat Commun. 2013;4:2192
pubmed: 23900241
Curr Opin Infect Dis. 2020 Feb;33(1):10-19
pubmed: 31789693
Can J Diabetes. 2015 Aug;39(4):250-2
pubmed: 26233723
Front Immunol. 2019 Mar 18;10:465
pubmed: 30967860
Antonie Van Leeuwenhoek. 2018 Jun;111(6):859-873
pubmed: 29460206
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):228-36
pubmed: 27171741
AIDS Res Ther. 2020 Mar 10;17(1):10
pubmed: 32156291
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Genome Biol. 2014;15(12):550
pubmed: 25516281
ISME J. 2018 Aug;12(8):1964-1976
pubmed: 29789624
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
Clin Infect Dis. 2020 Jan 02;:
pubmed: 31894240
Gut. 2014 May;63(5):727-35
pubmed: 23804561
Nat Med. 2020 Jun;26(6):919-931
pubmed: 32451498
Gut. 2019 Mar;68(3):453-464
pubmed: 30064988
PLoS Pathog. 2014 Feb 20;10(2):e1003829
pubmed: 24586144
Diabetologia. 2019 Jun;62(6):1024-1035
pubmed: 30904939
Drug Des Devel Ther. 2017 May 16;11:1481-1488
pubmed: 28553078
Cell Host Microbe. 2013 Sep 11;14(3):329-39
pubmed: 24034618
Cell Metab. 2019 Sep 3;30(3):462-476.e6
pubmed: 31471173
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Appl Environ Microbiol. 2015 Jun;81(11):3655-62
pubmed: 25795669
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
Curr HIV/AIDS Rep. 2019 Jun;16(3):204-213
pubmed: 31037552
mBio. 2017 Sep 19;8(5):
pubmed: 28928206
Gut. 2018 Jul;67(7):1269-1279
pubmed: 29101261
Atherosclerosis. 2015 Sep;242(1):167-73
pubmed: 26188541
J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):439-447
pubmed: 28471838
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):972-7
pubmed: 23277563
EBioMedicine. 2019 Aug;46:522-531
pubmed: 31327693
Infection. 2019 Feb;47(1):95-102
pubmed: 30269210
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389
pubmed: 31606734
Mucosal Immunol. 2015 Jul;8(4):760-72
pubmed: 25407519
AIDS. 2019 May 1;33(6):1001-1011
pubmed: 30946154
J Virus Erad. 2017 Oct 1;3(4):212-217
pubmed: 29057085
Clin Microbiol Rev. 2013 Jan;26(1):2-18
pubmed: 23297256
EBioMedicine. 2018 Apr;30:192-202
pubmed: 29650491
Sci Rep. 2017 Jul 24;7(1):6269
pubmed: 28740260
Nat Metab. 2019 Dec;1(12):1202-1208
pubmed: 32694673
Nutr Rev. 2019 Jan 1;77(1):46-63
pubmed: 30307550
Diabetologia. 2017 Sep;60(9):1662-1667
pubmed: 28770326
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
AIDS Res Hum Retroviruses. 2020 Apr;36(4):303-305
pubmed: 31731885
Nat Med. 2017 Jul;23(7):850-858
pubmed: 28530702
Drugs. 2016 Apr;76(5):533-49
pubmed: 26915027
Front Physiol. 2018 Jun 25;9:775
pubmed: 29988585
Heart Vessels. 2009 Nov;24(6):446-53
pubmed: 20108078
Mucosal Immunol. 2014 Jul;7(4):983-94
pubmed: 24399150
Nature. 2020 Feb;578(7795):444-448
pubmed: 31875646
Front Immunol. 2020 Apr 09;11:645
pubmed: 32328074
Nat Commun. 2020 May 15;11(1):2448
pubmed: 32415070
AIDS. 2016 Nov 13;30(17):2635-2643
pubmed: 27603289
PLoS One. 2010 Jan 18;5(1):e8758
pubmed: 20090912
PLoS One. 2018 Sep 27;13(9):e0204317
pubmed: 30261008
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71
pubmed: 23671105
Diabet Med. 1992 Jan-Feb;9(1):61-5
pubmed: 1551312
Biochem Biophys Res Commun. 2012 Sep 7;425(4):866-72
pubmed: 22898050
Front Immunol. 2019 Jan 25;9:3072
pubmed: 30761155
Front Microbiol. 2018 Jul 02;9:1451
pubmed: 30034377
AIDS. 2015 Nov 28;29(18):2409-18
pubmed: 26355675